89 related articles for article (PubMed ID: 15228672)
1. [Unrelated HLA-matched donor marrow transplantation for one case of myelodysplastic syndrome].
Gao CJ; Da WM; Zhang BL; Han XP; Zhu HY; Jin HJ; Jing Y; Huang WR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):378-80. PubMed ID: 15228672
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
3. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
4. [Unrelated or sibling donor allogeneic bone marrow transplantation for myelodysplastic syndrome].
Huang H; Lin M; Meng H
Zhonghua Nei Ke Za Zhi; 2000 Oct; 39(10):664-6. PubMed ID: 11374171
[TBL] [Abstract][Full Text] [Related]
5. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
[TBL] [Abstract][Full Text] [Related]
6. [Unrelated donor peripheral blood stem cell transplantation for hematologic malignancies].
Gao CJ; DA WM; Zhang BL; Han XP; Jing Y; Li HH; Bo J; Zhu HY; Jin HJ; Wu XX; Wang QX; Li SS; Huang WR; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):112-5. PubMed ID: 16584604
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of thalassemia major with unrelated donor bone marrow transplantation].
Zhu WG; Feng ZC; Lan HK; Zhang CC; Li QP; Li ZD
Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):599-602. PubMed ID: 16191272
[TBL] [Abstract][Full Text] [Related]
8. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.
Grunwald MR; Zhang MJ; Elmariah H; Johnson MH; St Martin A; Bashey A; Battiwalla M; Bredeson CN; Copelan E; Cutler CS; George BR; Gupta V; Kanakry C; Mehta RS; Milano F; Mussetti A; Nakamura R; Nishihori T; Saber W; Solh M; Weisdorf DJ; Eapen M
Blood Adv; 2021 Feb; 5(4):975-983. PubMed ID: 33576783
[TBL] [Abstract][Full Text] [Related]
9. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
10. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
13. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of myelodysplastic syndrome by hematopoietic stem cell transplantation combined with Chinese medical syndrome typing: a clinical study].
Zhang Y; Ye BD; Qian LL; Gao YT; Wen XW; Shen JP; Zhou YH
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):53-6. PubMed ID: 25790675
[TBL] [Abstract][Full Text] [Related]
16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
17. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
[TBL] [Abstract][Full Text] [Related]
18. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
20. Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation.
Kanda J; Ichinohe T; Fuji S; Maeda Y; Ohashi K; Fukuda T; Miyamura K; Iwato K; Eto T; Nakamae H; Kobayashi N; Mori T; Mori S; Morishima Y; Atsuta Y; Kanda Y;
Biol Blood Marrow Transplant; 2015 Feb; 21(2):305-11. PubMed ID: 25464119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
